Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P14784

UPID:
IL2RB_HUMAN

ALTERNATIVE NAMES:
High affinity IL-2 receptor subunit beta; Interleukin-15 receptor subunit beta; p70-75

ALTERNATIVE UPACC:
P14784; B2R765

BACKGROUND:
Interleukin-2 receptor subunit beta, known alternatively as p70-75, is integral for IL2 signal transduction and plays a significant role in immune response modulation. Its association with IL15RA is essential for IL15-induced neutrophil phagocytosis, highlighting its importance in immune system functioning.

THERAPEUTIC SIGNIFICANCE:
Given its association with Immunodeficiency 63, characterized by severe immune dysregulation, the study of Interleukin-2 receptor subunit beta could lead to breakthroughs in managing autoimmune diseases and immunodeficiencies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.